The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomas

Objective: Carcinosarcoma of the ovary and uterus represent rare, highly aggressive malignancies associated with poor survival outcomes. PARP inhibitors represent novel treatment options for cancers with underlying impaired DNA repair via homologous recombination mechanisms. We used whole exome sequencing (WES) data from a large cohort of carcinosarcoma patients to investigate whether ovarian (OCS) and uterine carcinosarcoma (UCS) possess the...